share_log

普洛药业获国信证券买入评级,业绩持续增长,原料药制剂一体化布局稳步推进

JRJ Finance ·  Aug 26 10:07  · Ratings

8月26日,普洛药业获国信证券买入评级,近一个月普洛药业获得7份研报关注。

研报预计,2024上半年百洛药业单季利润再创新高,实现营收64.29亿元,增长8.0%;归母净利润为6.25亿元,增长4.0%;扣非归母净利润6.02亿元,增长1.2%。其次,各业务板块发展稳健,研发全力推进,项目数持续增长,并在原料药制剂一体化布局中稳步推进。公司产品结构调整逐步到位,原料药制剂一体化战略顺利推进,并有多个项目达到了商业化阶段。研报认为,公司将持续注重各板块的协同管理与发展,未来增长潜力可期;原料药制剂一体化布局稳步推进,维持“优于大市”评级。

风险提示:地缘政治风险;行业竞争加剧风险;研发失败风险。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment